Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02621151
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
- NCT02621151 ↗
- Completed
- NYU Langone Health
- Focused
We haven't built an HCP commentary report on NCT02621151 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02621151 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Muscle-invasive Urothelial Cancer of the Bladder
- Interventions
- Pembrolizumab; Transurethral Resection of Bladder Tumor; Gemcitabine; External Beam Radiation Therapy
- Arms
- Pembrolizumab, Gemcitabine, and RT · Experimental
- Enrollment
- 60
- Primary outcomes
- Percentage of Participants Who Achieved Two-year Bladder-intact Disease-free Survival
- Sponsor
- NYU Langone Health with Merck Sharp & Dohme LLC
- Start
- Aug 11, 2016
- Primary completion
- Nov 10, 2022
- Results posted
- Yes
- Registry record
- NCT02621151 · updated Sep 30, 2026